Successful allogeneic stem cell transplant for leukocyte adhesion deficiency using an adjusted busulfan-containing regimen

Pediatric Transplantation

Volumn 11, Issue 4, 2007, Pages 453-455

  Yoshimoto, Akira ^a   Hashii, Yoshiko ^a,d   Kashiwagi, Hiroko ^a   Koizumi, Makoto ^a   Tokimasa, Sadao ^a   Fujisaki, Hiroyuki ^a   Ohta, Hideaki ^a   Hanai, Naomi ^b   Ozono, Keiichi ^a   Hara, Junichi ^c  

^a OSAKA UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Busulfan; Css; HSCT; Individual dose; LAD; Pharmacokinetics

Indexed keywords

BUSULFAN; CD18 ANTIGEN; COTRIMOXAZOLE; FLUCONAZOLE; FLUDARABINE; MEROPENEM; METHOTREXATE; MICAFUNGIN; TACROLIMUS; TEICOPLANIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; CASE REPORT; CHILD; DISEASE SEVERITY; DOSE CALCULATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNE DEFICIENCY; INFECTION PREVENTION; LEUKOCYTE ADHERENCE DEFICIENCY; LEUKOCYTE ADHERENCE INHIBITION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; RARE DISEASE; SIBLING; STREPTOCOCCUS INFECTION;

BUSULFAN; FOLLOW-UP STUDIES; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; LEUKOCYTE-ADHESION DEFICIENCY SYNDROME; MALE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 34247635256     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2007.00723.x     Document Type: Article

References (9)

1. Anderson DC, Springer TA. Leukocyte adhesion deficiency: An inherited defect in the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med 1987 : 38 : 175 194.
2. Lekstrom-himes JA, Gallin JI. Immunodeficiency diseases caused by defects in phagocytes. N Engl J Med 2000 : 343 : 1703 1714.
3. Thomas C, Le Deist F, Cavazzana-Calvo M, et al. Results of allogeneic bone marrow transplantation in patients with leukocyte adhesion deficiency. Blood 1995 : 86 : 1629 1635.
4. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 1998 : 20 : 543 549.
5. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant 2001 : 28 : 1013 1018.
6. Farinha NJ, Duval M, Wagner E, et al. Unrelated bone marrow transplantation for leukocyte adhesion deficiency. Bone Marrow Transplant 2002 : 30 : 979 981.
7. Sokolic RA, Bauer TR, Gu YC, et al. Nonmyeloablative conditioning with busulfan before matched littermate bone marrow transplantation results in reversal of the disease phenotype in canine leukocyte adhesion deficiency. Biol Blood Marrow Transplant 2005 : 11 : 755 763.
8. Rao K, Amrolia PJ, Jones A, et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005 : 105 : 879 885.
9. Savage WJ, Bleesing JJ, Douek D, et al. Lymphocyte reconstitution following non-myeloablative hematopoietic stem cell transplantation follows two patterns depending on age and donor/recipient chimerism. Bone Marrow Transplant 2001 : 28 : 463 471.